ZUMWALT LEANNE M 4
4 · Akebia Therapeutics, Inc. · Filed Jun 22, 2026
Research Summary
AI-generated summary of this filing
Akebia (AKBA) Director Leanne Zumwalt Receives RSUs and Option
What Happened
Leanne M. Zumwalt, a director of Akebia Therapeutics, was granted two equity awards on 2026-06-17: 35,700 restricted stock units (RSUs) and a stock option covering 53,600 shares. Both awards show an acquisition price of $0.00 (typical for grants); no cash changed hands. These are compensation grants (not open-market purchases or sales).
Key Details
- Transaction date: 2026-06-17; Form 4 filed 2026-06-22 (filed 5 days after the transaction; appears later than the typical 2-business-day Form 4 deadline).
- RSUs: 35,700 shares granted at $0.00.
- Stock Option (derivative): option for 53,600 shares granted at $0.00.
- Vesting: Both awards vest 100% on the first anniversary of the grant date (or earlier, immediately prior to the first annual meeting), subject to continuous service (per footnotes F1 and F2).
- Shares owned after the reported transaction: not specified in the filing.
- Plan/Program: Grants made under Akebia’s 2023 Stock Incentive Plan and the Non-Employee Director Compensation Program.
Context
RSUs represent a right to receive shares upon vesting; the stock option gives the holder the right to purchase shares after vesting. Because these are compensation awards (grants) rather than purchases or sales, they are routine director pay and do not by themselves indicate buying/selling sentiment. The filing delay is noted above; late Form 4s can draw regulatory attention but do not change the nature of the grants.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-17+35,700→ 145,100 total - Award
Stock Option (Right to buy)
[F2]2026-06-17+53,600→ 53,600 totalExercise: $1.02From: 2027-06-17Exp: 2036-06-17→ Common Stock (53,600 underlying)
Footnotes (2)
- [F1]The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
- [F2]The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.